Syndax Pharmaceuticals, Inc. (SNDX) Income Statement

The 91.8% sequential growth in 2026Q2 to $72.8M reflects the recognition of a significant milestone, likely tied to the NDA acceptance for revumenib. However, the underlying trend is lumpy: revenue was only $3.5M in 2024Q2 and $7.7M in 2024Q4, indicating that the recent spike is event-driven. Investors should monitor the transition to product sales, as the current revenue base is not indicative of future commercial performance.

The near-100% gross margin is a temporary artifact of collaboration revenue, which carries no cost of goods sold. As the company moves toward commercialization, gross margins will likely contract as manufacturing and distribution costs emerge. The operating margin, though improving from -182.7% in 2025Q2 to -54.9% in 2026Q2, is still far from breakeven, and the absolute operating loss of $40.0M in 2026Q2 underscores the capital-intensive nature of late-stage development.

The company's cost structure is heavily fixed, with R&D expenses consistently above $60M per quarter and SG&A rising to $41.5M in 2026Q2 as commercial preparations intensify. While revenue growth has been rapid, it is not scaling with expenses, and the operating loss of $40.0M in 2026Q2 is only slightly better than the $69.4M loss a year earlier. This suggests that the company is still in investment mode, and operating leverage will only materialize if revenue becomes recurring and grows faster than the cost base.

R&D spending is the largest cost line, at $68.0M in 2026Q2, consistent with the company's late-stage pipeline. SG&A has increased from $23.0M in 2024Q1 to $41.5M in 2026Q2, indicating preparation for a potential launch. This cost escalation is typical for a pre-commercial biotech, but it puts pressure on the balance sheet. The company's ability to manage these costs while advancing its pipeline will be critical to extending its cash runway.

The acceptance of the NDA for revumenib is a pivotal event, as it validates the clinical data and sets the stage for potential approval. The associated milestone revenue from Incyte provided a temporary boost to the income statement, but the lasting impact will be the shift in focus to regulatory approval and launch execution. This inflection point is critical because it changes the risk profile from clinical to commercial, and the company's ability to execute on a successful launch will determine its long-term financial trajectory.